AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation

Key Inclusion Criteria: * Participant with clinical diagnosis of acne vulgaris, defined by: 1. moderate acne on the face (acne Investigator's Global Assessment \[IGA\] =3); and 2. with minimum of 20 inflammatory lesions and 25 non inflammatory lesions on the face (excluding the nose); and 3. moderate to marked PIH on the face (Overview of Pigmentation Disorders hyperpigmentation scale 4-6); and 4. no more than one acne nodule or cyst (greater than \[\>\] 1 centimeter \[cm\]) on face (excluding the nose) * Participant with any Fitzpatrick Skin Type I to VI (target patient enrollment according to FST) * Female participants of childbearing potential must have a negative urine pregnancy test (UPT) at Baseline visit * Female participants of childbearing potential must agree to use an adequate and approved method of contraception throughout the study * Female participant of non-childbearing potential * Other protocol defined inclusion criteria could apply Key Exclusion Criteria: * Participant with severe acne (IGA \> 3) * Participant with more than 1 nodule/cyst on the face (excluding the nose) * Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne, acne requiring systemic treatment * Participant with damaged facial skin that may interfere with study assessments * Female participant who is pregnant, lactating or planning a pregnancy during the study * Female participant of childbearing potential using combined oral contraceptives approved as acne treatments, in whom the dose has not been stable for at least 6 months prior to the Baseline visit * Participant with known impaired hepatic or renal functions * Participant with active or chronic skin allergies